Trial results for a cohort study investigating Chronic Obstructive Pulmonary Disease (COPD) phenotypes and endotypes in China were posted on 2025-08-20, revealing exacerbation rates up to 0.35 per participant per year in GOLD Grade IV COPD patients.
Background
Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease characterized by airflow limitation, often leading to significant morbidity and mortality. Exacerbations, or acute worsenings of symptoms, are critical events in COPD progression, impacting quality of life and increasing healthcare burden. Understanding the clinical, radiological, and biological factors associated with disease progression, as well as the rates of exacerbations across different disease severities, is crucial for improving patient management. This cohort study aimed to investigate these factors within the Chinese population, specifically examining COPD phenotypes and endotypes.
Trial design
This completed non-drug interventional cohort study enrolled 2005 participants to investigate Pulmonary Disease, Chronic Obstructive. The study aimed to investigate the clinical, radiological, and biological factors associated with disease progression in COPD in China. Participants were recruited from multiple hospitals across Guangdong province.
Key results
The study reported several key measurements related to exacerbation rates and symptom burden:
- Rate of Moderate/Severe Exacerbations in COPD and Chronic Bronchitis Cohorts (Exacerbations per participant per year):
- Participants with COPD - GOLD Grade I: 0.08
- Participants with COPD - GOLD Grade II: 0.12
- Participants with COPD - GOLD Grade III: 0.26
- Participants with COPD - GOLD Grade IV: 0.35
- Participants with Chronic Bronchitis: 0.02
- Change From Baseline in COPD Assessment Test (CAT) Score at Month 30 (Scores on a scale):
- COPD Participants: Mean -0.9 (Standard Deviation 5.84)
- Participants with Chronic Bronchitis: Mean -2.3 (Standard Deviation 5.45)
- Never Smoker Healthy Control: Mean 0.3 (Standard Deviation 2.46)
- Absolute Values of CAT Score at Month 30 (Scores on a scale):
- COPD Participants: Mean 7.5 (Standard Deviation 5.33)
- Participants with Chronic Bronchitis: Mean 5.7 (Standard Deviation 4.18)
- Never Smoker Healthy Control: Mean 1.3 (Standard Deviation 2.36)
- Total Score of COPD Assessment in Primary Care to Identify Undiagnosed Respiratory Disease and Exacerbation Risk (CAPTURE) at Baseline (Scores on a scale):
- COPD Participants: Mean 2.6 (Standard Deviation 1.48)
What this means
The posted results provide valuable observational data on the rates of moderate/severe exacerbations and changes in COPD Assessment Test (CAT) scores within a large Chinese cohort. The findings indicate a clear trend of increasing exacerbation rates with higher GOLD grades of COPD severity. For instance, GOLD Grade IV participants experienced significantly higher exacerbation rates compared to those in GOLD Grade I. The changes in CAT scores over 30 months suggest a slight improvement in symptom burden for COPD and chronic bronchitis participants, while healthy controls showed a minor increase. This data contributes to a better understanding of disease progression and symptom burden in COPD patients in China, which can inform regional clinical practice and future research into specific phenotypes and endotypes.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT04853225, titled "Investigation of Chronic Obstructive Pulmonary Disease (COPD) Phenotypes and Endotypes in China", were posted on 2025-08-20 on clinicaltrials.gov.